Skip to main content

Advertisement

SpringerLink
Log in

Glucocorticoid-Induced Osteoporosis (GIOP)

  • Review Article
  • Published:
Indian Journal of Orthopaedics Aims and scope Submit manuscript

A Correction to this article was published on 11 December 2023

This article has been updated

Abstract

Use of glucocorticoid in various diseases including rheumatology and respiratory diseases is on the rise because of its prompt beneficial effects. This culminates in osteoporosis and fragility fractures. Judicious use of glucocorticoid hence calls for attention with regard to the dose schedule, route of administration and accompanying enhancing factors. Institution of proper therapeutic management as per WHO risk stratification with anabolic and/or resorptive drugs like bisphosphonates, teriparatide or denosumab is necessary to prevent the eventuality of fragility fractures. Even otherwise, knowledge of glucocorticoid, its metabolism, various dose schedules, adverse effects are areas worth discussing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Not applicable.

Change history

References

  1. Buckley, L., Guyatta, G., Fink, H. A., et al. (2017). 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid induced osteoporosis. Arthrtitis and Rheumatology., 69, 1521–1537.

    Article  Google Scholar 

  2. Buttgereit, F., Mehta, D., Kinwan, J., et al. (2013). Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomized clinical trial (CAPRA-2). Annals of the Rheumatic Diseases, 72, 204–210.

    Article  CAS  PubMed  Google Scholar 

  3. Canalis, E., Mazziotti, G., Giustina, A., & Bilezikian, J. (2007). Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporosis International, 18(10), 1319–1328.

    Article  CAS  PubMed  Google Scholar 

  4. Curtis, J. R., Westfall, A. D., Allison, J., et al. (2006). Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis and Rheumatism, 55, 420–426.

    Article  PubMed  Google Scholar 

  5. Eagan, T. M., Ueland, T., Wagner, P. D., et al. (2010). Systemic inflammatory markers in COPD: Results from the Bergen COPD Cohort study. European Respiratory Journal, 35(3), 540–548.

    Article  CAS  PubMed  Google Scholar 

  6. Fujimoto, H., Fujimoto, K. S., Ueda, A., & Ohata, M. (1999). Hypoxemia is a risk factor for bone mass loss. Journal of Bone and Mineral Metabolism, 17(3), 211–216.

    Article  CAS  PubMed  Google Scholar 

  7. Garcia-Rio, F., Miravitlles, M., Soriano, J. B., et al. (2010). EPI-SCAN steering committee systemic inflammation in chronic obstructive pulmonary disease: A population-based study. Respiratory Research, 11, 63.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hench, P. S., Kendall, E. C., Slocumb, C. H., et al. (1949). The effect of a hormone of the adrenal cortex (17 hydroxy-11-dehydrocorticosterone: Compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis: Preliminary report. Proceedings of the Staff Meetings Mayo Clinic, 24, 181–197.

    CAS  PubMed  Google Scholar 

  9. Huscher, D., Thiele, K., Gromnica-Ihle, E., et al. (2009). Dose-related patterns of glucocorticoid-induced side effects. Annals of the Rheumatic Diseases, 68, 1119–1124.

    Article  CAS  PubMed  Google Scholar 

  10. Jilka, R. L., Noble, B., & Weinstein, R. S. (2013). Osteocyte apoptosis. Bone, 54(2), 264–271.

    Article  PubMed  Google Scholar 

  11. Korkmaz, U., Korkmaz, N., & Yazici, S. (2012). Anemia as a risk factor for low bone mineral density in postmenopausal Turkish women. European Journal of Internal Medicine, 23(2), 154–158.

    Article  PubMed  Google Scholar 

  12. Maricic, M. (2011). Update on glucocorticoidinduced osteoporosis. Rheumatic Diseases Clinics of North America, 37, 415–431.

    Article  PubMed  Google Scholar 

  13. Ong, T., Sahota, O., Tan, W., & Marshall, L. A. (2014). United Kingdom perspective on the relationship between body mass index (BMI) and bone health: A cross sectional analysis of data from the Nottingham Fracture Liaison Service. Bone, 59, 207–210.

    Article  PubMed  Google Scholar 

  14. Painter, S. E., Klerrekoper, M., & Camacho, P. M. (2006). Secondary osteoporosis: A review of the recent evidence. Endocer Pract., 12, 436–445.

    Article  Google Scholar 

  15. Peters, M. J., Symmons, D. P., McCarey, D., et al. (2010). EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of infl ammatory arthritis. Annals of the Rheumatic Diseases, 69, 325–331.

    Article  CAS  PubMed  Google Scholar 

  16. Piper, J. M., Ray, W. A., Daugherty, J. R., & Griffin, M. R. (1991). Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs. Annals of Internal Medicine, 114, 735–740.

    Article  CAS  PubMed  Google Scholar 

  17. Richter, B., Nelses, G., & Clar, C. (2002). Glucocorticoid withdrawal schemes in chronic medical disorders. A systemic review. Endocrinology and Metabolism Clinics of North America., 31, 751–778.

    Article  CAS  PubMed  Google Scholar 

  18. Sang, K., & Buttgereit, F., et al. (2019). Systemic glucocorticoid therapy in rheumatology. In M. C. Hochberg (Ed.), Rheumatology (7th ed., pp. 488–498). Elsevier.

    Google Scholar 

  19. Sapey, E., Ahmad, A., Bayley, D., et al. (2009). Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. Journal of Clinical Immunology, 29(4), 508–516.

    Article  CAS  PubMed  Google Scholar 

  20. Stahn, C., & Buttgereit, F. (2008). Genomic and nongenomic effects of glucocorticoids. Nature Clinical Practice Rheumatology, 4, 525–533.

    Article  CAS  PubMed  Google Scholar 

  21. Théoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004). The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling. Cytokine & Growth Factor Reviews, 15, 457–475.

    Article  Google Scholar 

  22. Tripathi, R. C., Parapuram, S. K., Tripathi, B. J., Zhong, Y., & Chalam, K. V. (1999). Corticosteroids and glaucoma risk. Drugs and Aging, 15, 439–450.

    Article  CAS  PubMed  Google Scholar 

  23. Wang, Y., Wan, C., Deng, L., Liu, X., Cao, X., Gilbert, S. R., et al. (2007). The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. The Journal of Clinical Investigation, 117, 1616–1626.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Weinstein, R. S. (2011). Clinical Practice. lucocorticoid—nduced bone disease. New England Journal of Medicine, 365, 62–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harishchandra Institute of Orthopaedics and Research, Patna, India

    S. S. Jha

  2. IOA Orthopaedic Rheumatology Subcommittee, New Delhi, India

    S. S. Jha

  3. IOA Osteoporosis Subcommittee, New Delhi, India

    S. S. Jha

  4. Innovative Education and Scientific Research Foundation, New Delhi, India

    S. S. Jha

Authors
  1. S. S. Jha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. S. Jha.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard statement

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Informed consent

For this type of study, informed consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: In this article the title was incorrectly given as ‘Chapter 22: Glucocorticoid-Induced Osteoporosis (GIOP)’ but should have been ‘Glucocorticoid-Induced Osteoporosis (GIOP)’.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jha, S.S. Glucocorticoid-Induced Osteoporosis (GIOP). JOIO 57 (Suppl 1), 181–191 (2023). https://doi.org/10.1007/s43465-023-01037-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43465-023-01037-8

Keywords

Search

Navigation